亚太地区碳青霉烯类抗生素市场预测至 2028 年 - COVID-19 影响和区域分析（按类型（美罗培南、多尼培南、亚胺培南、替比培南等）、适应症（细菌性脑膜炎、急性盆腔感染、呼吸道感染、腹内感染）） 、尿路感染等）和分销渠道（零售药房、网上药房、医院药房）
No. of Pages: 152 | Report Code: TIPRE00028784 | Category: Life Sciences
No. of Pages: 152 | Report Code: TIPRE00028784 | Category: Life Sciences
市场的增长归因于流行率上升等因素细菌感染和增加领先制药企业的私人和公共伙伴关系。然而，繁琐且昂贵的抗生素开发过程预计将在预测期内限制市场的增长。
仿制药因其可用性和价格实惠而广受欢迎。此外，碳青霉烯类抗生素专利的到期为仿制药制造商以其具有成本效益的药物进入市场提供了更多机会。仿制药生产商的主要关注点是扩大这些药物的覆盖范围。此外，治疗细菌感染的抗生素短缺也是推动市场的主要因素之一。通用碳青霉烯类抗生素产量的增加增加了各个低收入和中等收入国家的药物供应量。
市场上可用的碳青霉烯类药物的仿制药有厄他培南 (Invanz)、亚胺培南/西司他丁 (Primaxin IM)、多尼培南 (Doribax) 和美罗培南 (Merrem)。此外，市场上越来越多的仿制药厂商正在加速仿制药的生产。许多亚洲公司正在开发活性药物成分（API），这是生产通用碳青霉烯类抗生素所必需的。 2021年6月，韩国JW制药公司宣布已完成厄他培南注射液原料药的生产，并运往美国。该公司计划在未来几年进入全球碳青霉烯类抗生素市场。它还在韩国成功地自主开发了生产多尼培南的技术。此外，公司还计划扩大亚胺培南、美罗培南原料药和成品药的销售，出口到中国、日本等40多个国家。因此，企业加速仿制药生产正在推动全球碳青霉烯类抗生素市场的发展。
亚太地区碳青霉烯类抗生素市场细分
Strategic insights for Asia Pacific Carbapenem-Based Antibiotics involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.
| Report Attribute | Details |
|---|---|
| Market size in 2021 | US$ 1,072.76 Million |
| Market Size by 2028 | US$ 1,506.07 Million |
| Global CAGR (2021 - 2028) | 5.0% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By 类型
|
| Regions and Countries Covered | 亚太地区
|
| Market leaders and key company profiles |
The regional scope of Asia Pacific Carbapenem-Based Antibiotics refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.
The Asia Pacific Carbapenem-Based Antibiotics Market is valued at US$ 1,072.76 Million in 2021, it is projected to reach US$ 1,506.07 Million by 2028.
As per our report Asia Pacific Carbapenem-Based Antibiotics Market, the market size is valued at US$ 1,072.76 Million in 2021, projecting it to reach US$ 1,506.07 Million by 2028. This translates to a CAGR of approximately 5.0% during the forecast period.
The Asia Pacific Carbapenem-Based Antibiotics Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Carbapenem-Based Antibiotics Market report:
The Asia Pacific Carbapenem-Based Antibiotics Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Carbapenem-Based Antibiotics Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Carbapenem-Based Antibiotics Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Carbapenem-Based Antibiotics Market
